Abstract
Infliximab (REMICADE®, Centocor), a chimeric anti-TNFα monoclonal antibody, has been used in the management of patients with steroid-refractory acute GVHD. Though preliminary results using infliximab have been encouraging, the pharmacokinetics (Pk) of infliximab in this clinical setting have yet to be defined. A prospective trial examining the Pk of infliximab in pediatric patients with gastrointestinal (GI) GVHD was undertaken. Five subjects (median 11 yrs, range 9 mo–17 yrs) with GI GVHD were enrolled.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
